Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.
Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
The new drug application is for doravirine as both an individual tablet and part of a combination tablet.
The new single-tablet NNRTI regimen was less likely than Atripla to cause neurological symptoms.
Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.